Clinical trials
Soft Tissue Sarcoma clinical trials
Below are recruiting soft tissue sarcoma clinical trials, each written for real people, not researchers. We’re tracking 181 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05539677Recruiting
Research biobank and patient registry for aggressive solid tumors
This study builds a biobank and patient registry using tumor samples and blood. It helps researchers better understand aggressive cancers and may improve future treatments by testing immune (defense) responses.
Saint PetersburgAges 1 year+ - NCT05597917RecruitingPhase 3
Test drug trabectedin for advanced soft-tissue sarcoma
This Phase 3 trial tests trabectedin (in tTF-NGR study) for people with advanced or metastatic soft-tissue sarcoma whose first treatment with anthracycline drugs didn’t work (or can’t be used). It aims to see if this approach works better than the study comparison treatment, using tumor response and other safety outcomes.
Bad SaarowAges 18–75 - NCT05617859RecruitingPhase 2
Lenvatinib treatment for advanced bone or soft tissue sarcoma
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
Zhengzhou, HenanAges 10–70 - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT05917301Recruiting
Pre-surgery proton radiation for soft tissue sarcoma
This trial studies a shorter-course proton radiation plan given before surgery for certain soft tissue sarcomas. The goal is to treat the tumor locally while helping surgery be safer or more effective.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05926700RecruitingPhase 2
Testing cadonilimab plus anlotinib for advanced soft tissue sarcoma
This Phase 2 study tests two medicines (cadonilimab and anlotinib) in people with advanced soft tissue sarcoma whose cancer grew after standard first treatment. It aims to see whether the combination can shrink tumors and improve safety.
HangzhouAges 18 years+ - NCT05944913Recruiting
Testing a special wound dressing after sarcoma tumor removal
This trial compares two types of wound dressings after surgery for soft-tissue sarcoma (STS) that has had radiation therapy. It aims to see whether one dressing helps your wound heal better after tumor removal.
Nantes, Pays de LoireAges 18 years+ - NCT05955105RecruitingPhase 1/Phase 2
ILB-2109 plus toripalimab for advanced solid cancers
This Phase 1/2 study tests a combination medicine (ILB-2109) plus an immune therapy (toripalimab) in people with advanced solid tumors when standard treatments haven’t worked or aren’t available. It aims to find out if the treatment can shrink tumors and is safe enough to keep studying.
Jinan, ShandongAges 18–80 - NCT06332274RecruitingPhase 3
Tislelizumab for cancer patients with minimal residual disease
This trial is for people who have completed standard cancer treatments (like surgery, chemo or radiation) and have no visible cancer on scans, but may still have very small amounts of cancer DNA in their blood. The study tests whether the drug tislelizumab can help prevent the cancer from coming back.
Villejuif, Val De MarneAges 18 years+ - NCT06333314RecruitingPhase 2
Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
AngersAges 18 years+ - NCT06408441Recruiting
EHE registry for rare adult cancers
This study collects information from European hospitals on people with epithelioid hemangioendothelioma (EHE), a rare tumor that grows in blood vessels. Joining this registry helps doctors learn more about the disease and improve care for others.
Graz, GrazAges 18 years+ - NCT06645808RecruitingEarly Phase 1
PET imaging study for various solid tumors
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
Groningen, Provincie GroningenAges 18 years+ - NCT06700070RecruitingEarly Phase 1
Testing a microdose drug in solid tumors before surgery
This study tests a tiny amount of an experimental drug (PBA-0111) injected directly into tumors that will be surgically removed later. The goal is to see how the drug affects the tumor tissue, which may help guide future treatments for solid tumors like head and neck cancer, certain sarcomas, or triple-negative breast cancer.
Shreveport, LouisianaAges 18 years+ - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years - NCT06774729Recruiting
Predicting tumor spread using MRI in sarcoma or bone cancer
This trial uses MRI scans to create a model that may predict if a musculoskeletal tumor is spreading. It aims to help doctors decide on the best surgical treatment.
BolognaAges 18 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06967961Recruiting
Looking for cancer cells that carry two markers in the blood
This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.
ToulouseAges 18 years+ - NCT06988475RecruitingPhase 2/Phase 3
Capmatinib for cancers with MET gene changes
This study tests an oral drug called capmatinib for people whose cancers have specific changes in the MET gene (except for one type of lung cancer). It aims to see if the drug can shrink tumors or slow their growth.
BelfastAges 18 years+ - NCT07064018RecruitingPhase 1/Phase 2
SPEDOX-6 for advanced solid tumors
This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.
Orange, CaliforniaAges 18 years+ - NCT07261631RecruitingPhase 1
A study of a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
Montreal, QuebecAges 18–100 - NCT01898663RecruitingPhase 1/Phase 2
Vaccine plus immune cell therapy for adults with AML
This early-phase study tests a combined treatment—an immune “DC” vaccine plus specially trained killer immune cells—for adults with AML. The goal is to see if this approach is safe and can help control the disease.
BeijingAges 18 years+ - NCT07528079Enrolling by invitation
Personalized Chemotherapy for Children with Advanced Soft Tissue Tumors
This trial uses lab-grown tumor samples from your child to test which chemotherapy drugs work best for their specific cancer. The goal is to find the most effective treatment by testing medicines on their tumor cells before giving them to your child.
Shanghai, Shanghai MunicipalityAges 1–18 - NCT06789666Recruiting
Digital art therapy for young cancer survivors
This trial is testing a digital art therapy program designed to help young adults who survived childhood cancer feel better emotionally. You'll use an app to create art and connect with others, all from home.
Chapel Hill, North CarolinaAges 18–25
Hear when a new Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for soft tissue sarcoma?
- Yes. Clin2 currently lists 181 recruiting soft tissue sarcoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a soft tissue sarcoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a soft tissue sarcoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.